A5071784890- Head and Neck Cancer Studies
- Cancer Immunotherapy and Biomarkers
- Cancer Diagnosis and Treatment
- Head and Neck Surgical Oncology
- Lung Cancer Treatments and Mutations
- Advanced Radiotherapy Techniques
- Brain Metastases and Treatment
- Radiopharmaceutical Chemistry and Applications
- Lung Cancer Research Studies
- Cancer Genomics and Diagnostics
- Salivary Gland Tumors Diagnosis and Treatment
- Peptidase Inhibition and Analysis
- Ear and Head Tumors
- Pancreatic and Hepatic Oncology Research
- Immune cells in cancer
- Cancer, Hypoxia, and Metabolism
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Immunotherapy and Immune Responses
- Colorectal and Anal Carcinomas
- Monoclonal and Polyclonal Antibodies Research
- Lymphoma Diagnosis and Treatment
- Management of metastatic bone disease
- Virus-based gene therapy research
- Oral health in cancer treatment
- CAR-T cell therapy research
UPMC Hillman Cancer Center
2014-2025
University of Pittsburgh Medical Center
2014-2024
University of Pittsburgh
2011-2020
Pittsburg State University
2013
UPMC Health System
2013
Purpose: Exosomes, small extracellular vesicles (EVs) derived from the endocytic compartment of their parent cells, are present in plasma cancer patients and may serve as non-invasive biomarkers disease outcome. Here, we asked whether tumor-derived (TEX) and/or T-cell exosomes can predict outcome head neck squamous cell carcinoma (HNSCC) treated with oncological therapy.Materials Methods: 18 HNSCC enrolled phase I clinical trial receiving a combination cetuximab, ipilimumab radiation therapy...
Background Biliary tract cancers are rare, aggressive neoplasms. Most patients present with advanced/unresectable or metastatic disease at diagnosis, and no second‐line regimen has demonstrated clinical benefit. This was a phase 2 study evaluating the efficacy safety of regorafenib in who had after receiving standard therapy. Methods In this single arm‐study, biliary cancer failed least 1 line systemic chemotherapy received once daily on schedule 21‐days on/7‐days off 28‐day cycle. Patients...
We evaluated the addition of bevacizumab, a humanized monoclonal antibody that targets vascular endothelial growth factor, to platinum-based chemotherapy in recurrent or metastatic squamous cell carcinoma head and neck (SCCHN).Patients with chemotherapy-naïve (or prior platinum as part multimodal therapy completed ≥ 4 months earlier) SCCHN were randomly assigned receive doublet without bevacizumab 15 mg/kg given intravenously every 3 weeks until disease progression. Chemotherapy could be...
Abstract Multidisciplinary conferences (MDC) are an important component of head and neck oncologic care including diagnosis, treatment, survivorship. Virtual MDC allows for improved collaboration between providers at distant sites proper allocation health resources in a time crisis. When approached systematically, virtual is feasible to design implement large academic medical center with multiple satellite hospitals.
Abstract Background DNA mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC) is not responsive to pembrolizumab monotherapy. methyltransferase inhibitors can promote antitumor immune responses. This clinical trial investigated whether concurrent treatment with azacitidine enhances the activity of in mCRC. Methods We conducted a phase 2 single-arm evaluating and tolerability plus patients chemotherapy-refractory mCRC (NCT02260440). Patients received 200 mg IV on day 1 100 SQ...
BACKGROUND The objective of this study was to investigate the prevalence pathogenic germline variants (PGVs) in 32 cancer susceptibility genes individuals with newly diagnosed pancreatic ductal adenocarcinoma (PDAC). A key secondary evaluate how often PGVs would have been undetected existing genetic testing criteria. METHODS From May 2016 through 2017, multicenter cohort enrolled consecutive patients aged 18 89 years histologically confirmed PDAC within previous 12 weeks. Demographics,...
Abstract Purpose: The response rate of patients with head and neck squamous cell carcinoma (HNSCC) to cetuximab therapy is only 15% 20%, despite frequent EGFR overexpression. Because immunosuppression common in HNSCC, we hypothesized that adding a proinflammatory TLR8 agonist might result enhanced T-lymphocyte stimulation anti–EGFR-specific priming. Experimental Design: Fourteen previously untreated HNSCC were enrolled this neoadjuvant trial treated preoperatively 3 4 weekly doses motolimod...
Immune checkpoint blockade has demonstrated clinical benefits across multiple solid tumor types; however, resistance and relapse often occur. New immunomodulatory targets, which are highly expressed in activated immune cells, needed. MEDI0562, an agonistic humanized mAb, specifically binds to the costimulatory molecule OX40. This first-in-human study evaluated MEDI0562 adults with advanced tumors.In this phase I, multicenter, open-label, single-arm, dose-escalation (3+3 design) study,...
Optimizing the utilization of surveillance PET/CT in treated HNSCC is an area ongoing research. Our aim was to determine negative predictive value patients with head and neck squamous cell cancer whether reduces need for further imaging surveillance.We evaluated who underwent posttreatment PET/CT. During routine clinical readouts, scans were categorized as having negative, probably malignant, or malignant findings. We followed clinically radiographically at least 12 months from their last...
Abstract Purpose: Concurrent radiotherapy with cetuximab, an anti-EGFR mAb, is a standard treatment for locally advanced head and neck squamous carcinoma (HNSCC). Cytotoxic T lymphocyte antigen-4–positive (CTLA-4+) regulatory cells (Treg) dampen cellular immunity correlate negatively clinical outcomes. This phase I study added ipilimumab, anti–CTLA-4 to cetuximab-radiotherapy. Patients Methods: A (3 + 3) design was used establish the recommended II dose (RP2D) of at week 5 four, every-3-week...
6007 Background: Optimal timing, either concurrent or sequential, of anti-programmed death (PD)-1 antibody with chemoradiotherapy (CRT) for LA SCCHN is unknown. Recently, JAVELIN-100 showed no benefit adding avelumab to CRT. Methods: In this randomized, phase 2 study, patients (pts) intermediate risk human papillomavirus (HPV) positive oropharyngeal ( > 10 pack years T4 N3) HPV negative previously-untreated the oropharynx, hypopharynx, larynx, oral cavity (unselected PD-L1 status) were...
676 Background: Data is lacking to guide the care of vulnerable older adults (OA) with newly diagnosed metastatic pancreatic adenocarcinoma (mPDAC). EA2186 trial demonstrated poor outcomes among OA mPDAC treated dose-reduced chemotherapy. To understand factors driving treatment in this patient population, we analyzed correlation between baseline geriatric and quality life (QOL) assessments outcomes. Methods: Vulnerable ≥70 yo mPDAC, ECOG PS 0-2 were enrolled. Vulnerability was defined by...
Stereotactic body radiotherapy (SBRT) has been studied in locally recurrent previously-irradiated head and neck cancers; however, the optimum fractionation patient selection continues to be defined.Patients (n = 132) with cancer salvaged via SBRT ± cetuximab (median, 44 Gy/5 fractions) from November 2004 May 2011 were retrospectively reviewed. Disease outcomes toxicity analyzed by predictive factors including treatment duration tumor volume.At a median 6-month follow-up (range, 0-55 months),...
We previously reported numerically better efficacy with CRT sequential (S) vs. concurrent (C) pembrolizumab (P). now report updated results at 4-years and tumor-immune correlates. Patients (n=80) HPV (-) LA HNSCC intermediate risk + oropharyngeal (> 10 pack years or T4 N3) were randomized 1:1 to C (n=41) P starting 1 week prior (cisplatin 40 mg/m2 weekly RT 70 Gy in 35 fractions) S (n=39) 2 weeks after CRT. was 200mg q 3 X 8 doses. Biopsies pre on treatment (tx; during of CRT) available the...
Abstract Background Stereotactic body radiotherapy (SBRT) has emerged as a promising salvage strategy for patients with recurrent, previously irradiated head and neck cancer; however, data are limited predominantly to squamous cell carcinomas. Herein, we report the efficacy of SBRT in nonsquamous cancers (NSCHNs). Methods In all, 34 pathologically proven NSCHN were reirradiated median dose 40 Gy 5 fractions (interquartile range, 30–44 Gy). Toxicity quality life followed prospectively....
Patients with primary head and neck cancer managed radiation therapy (RT) +/- chemotherapy may experience significant treatment-related toxicities. We assessed hospitalization as a metric for severe toxicities evaluated patient treatment factors possible association.A retrospective review was performed on 147 patients treated definitive or adjuvant intensity-modulated (IMRT) chemotherapy. Multiple Poisson regression model used to analyze relationships between number of hospital stays during...
Adjuvant radiation therapy (RT) is indicated for patients with salivary gland malignancies risk factors recurrence following resection. We analyzed treated adjuvant RT or without concurrent chemotherapy to determine the impact of prognostic and treatment factors.Retrospective analysis was performed 128 surgical resection followed by intensity-modulated radiotherapy. In total, 31 (24.2%) were chemoradiotherapy. The Kaplan-Meier method used estimate rates progression-free survival (PFS),...
Locoregional recurrence remains the primary failure pattern following salvage surgery for previously irradiated head and neck cancer; randomized trials have suggested a complimentary role adjuvant chemotherapy conventional reirradiation at expense of significant increases in toxicity. We aimed to identify if stereotactic body radiotherapy (SBRT) ± cetuximab improves tumor control while reducing treatment-related toxicity surgery.Retrospective review (2005-2011) 28 patients with high-risk...